Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment

Fig. 3

IL-33 inhibited immune effector cells and mobilised immunosuppressive cells into the TME. Splenocytes and intrahepatic single-cell suspensions were harvested for flow cytometric analysis. a Percentages of tumour-infiltrating CD45+ leukocyte, CD3−NK1.1+ NK cells, CD4+Foxp3+ Tregs among total cells were determined by flow cytometry. b The percentages of activated CD69+CD4+ T and CD69+CD8+ T cells were presented. c IL-33 induced accumulation of splenic CD4+Foxp3+ Tregs. D, e Flow cytometry was used to analyse Gr1, Ly6G, and Ly6C expression in gated CD11c−CD11b+ cells. d IL-33 treatment increased the accumulation of CD11c−CD11b+Gr1+ MDSCs in tumour-bearing mice. e The percentages of CD11c−CD11b+Ly6G+Ly6Clow granulocytic and CD11c−CD11b+Ly6G−Ly6Chigh monocytic MDSCs were presented before and after IL-33 treatment. f–i Flow cytometry was used to analyse CD11c+, CD11c+CD11b+ in spleens, and MHCII+ and B220−MHCII+ expression in gated CD11c+CD11b+ cells. IL-33 increased the percentage of CD11c+ (f) and CD11c+CD11b+ cells (g), while it decreased the percentage of conventional CD11c+CD11b+B220−MHCII+ DCs cells (h, i). TME tumour microenvironment, MDSCs myeloid-derived suppressor cells, DCs dendritic cells, IL interleukin, Tregs regulatory T cells

Back to article page